Advancing Access to Psychedelic-Assisted Mental Health Treatments through Economic Analysis
Our Mission
CEP is a network of health economists and health services researchers
dedicated to fulfilling the potential of psychedelic therapies for
high-priority mental health conditions.
Through rigorous economic analyses, CEP provides insight and information to
healthcare payers, clinicians, and policy actors, enhancing access to these
promising therapies for all who can benefit. Below is a partial list of
current projects. This three-page summary provides additional information on CEP's mission
and activities.
Notable Achievements
In collaboration with the Multidisciplinary Association for Psychedelic
Studies (MAPS), evaluated the cost-effectiveness of MDMA-assisted therapy for people with chronic PTSD; and modeled the health
and economic effects of scaled-up access.In collaboration with the Usona Institute, modeling the cost-effectiveness of
psilocybin-assisted psychotherapy to treat Major Depressive Disorder. An additional study is now in peer review on the economics of psilocybin-assisted psychotherapy for Treatment-Resistant Depression.
Advisory Council
Rick Doblin, Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)
Tura Patterson, Senior Director, Strategic partnerships, Usona Institute
Matthew Johnson, Associate Center Director, Johns Hopkins University, Center for Psychedelics & Consciousness Research
Eduardo Schenberg, Founder, Instituto Phaneros (São Paolo, Brazil)
In collaboration with Johns Hopkins University’s Center for Psychedelic and Consciousness Research, evaluating the cost-effectiveness of psilocybin-assisted therapy for smoking cessation.
In collaboration with Sunstone Therapies and Social Neuroscience and Psychotherapy (SNaP) Lab, analyzed the effect of group psychedelic therapy on costs and cost-effectiveness and on the number of qualified clinicians required for scaled-up access to psychedelic therapies.
